CR9481A - Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos - Google Patents

Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos

Info

Publication number
CR9481A
CR9481A CR9481A CR9481A CR9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
mimeticbodies
glucagon
humans
Prior art date
Application number
CR9481A
Other languages
English (en)
Inventor
T O'neil Karyn
Picha Kristen
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CR9481A publication Critical patent/CR9481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere por lo menos un mimeticuerpo de GLP-1 humano novedoso o porcion o variante especificada, que incluye acidos nucleicos aislados que codifican por lo menos un mimeticuerpo de GLP-1 o porcion o variante especificada, mimeticuerpo de GLP-1 o porcion o variante especificadas, vectores, celulas hospedero, animales transgenicos o plantas, y metodos para hacer y usar los mismos, incluyendo composiciones terapeuticas, metodos y dispositivos.
CR9481A 2005-03-28 2007-10-29 Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos CR9481A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28

Publications (1)

Publication Number Publication Date
CR9481A true CR9481A (es) 2009-01-14

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9481A CR9481A (es) 2005-03-28 2007-10-29 Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos

Country Status (12)

Country Link
EP (1) EP1871811A4 (es)
JP (1) JP2008546373A (es)
KR (1) KR20080005378A (es)
CN (1) CN101389346A (es)
AU (1) AU2005339797A1 (es)
BR (1) BRPI0520168A2 (es)
CA (1) CA2603359A1 (es)
CR (1) CR9481A (es)
IL (1) IL186307A0 (es)
MX (1) MX2007011975A (es)
NO (1) NO20075272L (es)
WO (1) WO2007081302A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
CN111574583B (zh) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 蛋白复性试剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
KR20080085082A (ko) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
KR20050033563A (ko) * 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
WO2004002417A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2007081302A2 (en) 2007-07-19
AU2005339797A1 (en) 2007-07-19
MX2007011975A (es) 2008-03-14
WO2007081302A3 (en) 2008-11-13
NO20075272L (no) 2007-12-28
JP2008546373A (ja) 2008-12-25
KR20080005378A (ko) 2008-01-11
CA2603359A1 (en) 2007-07-19
BRPI0520168A2 (pt) 2009-04-22
CN101389346A (zh) 2009-03-18
EP1871811A2 (en) 2008-01-02
EP1871811A4 (en) 2009-07-22
IL186307A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
UY30494A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, métodos y usos
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
CR8320A (es) Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos
CR9606A (es) Anticuerpos anti-proteina quinoatrayente de monocitos-1, composiciones, metodos y usos
NI200700158A (es) Agonistas glp-1, composiciones, métodos y usos
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CR9443A (es) Vacuna de toxoide de c. perfringens alfa
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
CR9514A (es) Antagonistas de npy, preparacion y usos
UY30820A1 (es) Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
CR9481A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
DOP2006000117A (es) Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
UY27973A1 (es) Debencenoxazepinas
ES2337005R (es) Compuestos de pirazolina azepan o azocansustituidos, su preparacion y su uso como medicamentos.
CL2007003811A1 (es) Inhibidores de proteasa no naturales del tipo de kunitz que tienen entre 56-60 aminoacidos; acido nucleico que codifica un inhibidor de proteasa no natural; uso de dicho inhibidor para tratamiento de hemorragias.
AR030133A1 (es) Anticuerpos anti-tnf, composiciones, metodos y usos
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
DOP2003000696A (es) Debencenoxazepinas
GT200600212A (es) Anticuerpos anti-mcp-1, composiciones, metodos y usos
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
ECSP066764A (es) Compuestos de pirazolina sustituidos, su preparación y su uso como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)